A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes
Extended low-molecular-weight hepann treatment beyond the acute phase reduces the nkk of deatMmyocatdial infmction (MI) at 30 days in patients with unstable coronary artery disease (UCAD; unskable angina/mn Q-wave MI). Can riskstm@%ation determine which palients willbeneflmost? Highest risk: Primary PCI or lytics GP IlWllla-inhibitor7 Unstable angina Enyzmes neg., ECG neg. Non-Q-wave MI Unstable angina Enzymes neg., ECG ST-depelmm, Tk +Trop Low risk: Outpatient evaluation Enzymes neg., ECGdoi:10.1002/clc.4960241307 fatcat:72o5hul3knbm5etcrfoaakkzym